A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10504 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC
Latest Information Update: 20 Jun 2024
At a glance
- Drugs HS 10504 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 20 Jun 2024 New trial record